by Susan C Olmstead at The Defender
A Wall Street Journal (WSJ) editorial board member Monday called into question the motives behind the U.S. Food and Drug Administration’s (FDA) decision to extend Emergency Use Authorization of Pfizer and Moderna’s COVID-19 vaccines to toddlers and infants as young as 6 months old, writing that the decision was motivated by politics and pressure rather than science.
In her WSJ opinion piece — “Why the Rush for Toddler Vaccines?” — Allysia Finley wrote:
“The FDA standard for approving vaccines in otherwise healthy people, especially children, is supposed to be higher than for drugs that treat the sick.
“But the FDA conspicuously lowered its standards to approve COVID vaccines for toddlers. Why?”
Finley started her piece with a quote from President Biden, which praised the FDA’s recommendation: “This is a very historic milestone. The United States is now the first country in the world to offer safe and effective COVID-19 vaccines for children as young as six months old.”
She responded, writing, “In fact, we don’t know if the vaccines are safe and effective.”
She continued:…
Continue Reading